All In Biotech

Free tool

FAERS Monitor: Flector

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021234 or its brand name (Flector, Diclofenac Epolamine). Reports on generic versions are filed under their own applications.

Reports

4,227

Serious

1,478

35% of reports

Hospitalization

639

Death reported

116

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective648
  • pain274
  • drug hypersensitivity235
  • nausea220
  • off label use192
  • headache176
  • dizziness162
  • rash156
  • diarrhoea141
  • malaise141
  • fatigue140
  • pruritus132
  • fall129
  • dyspnoea120
  • pain in extremity111

Reports by year received

View as table
YearReports
20042
20051
20062
20073
200835
200943
2010590
2011164
2012584
2013260
2014198
2015224
2016276
2017231
2018309
2019379
2020315
2021204
2022125
202385
202459
202598
202640

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,932 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal2356.05.3993
drug ineffectiveSignal6482.42.3590
painSignal2742.22.0188
fall1291.91.658
pain in extremity1111.91.645
rash1561.81.554
pruritus1321.71.439
dizziness1621.61.438
malaise1411.61.432
headache1761.41.220
nausea2201.41.224
off label use1921.11.01
diarrhoea1411.10.91
dyspnoea1201.10.90
fatigue1400.90.82

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.